Snell & Wilmer represented Trawsfynydd Therapeutics, Inc. in the transaction, and Orrick, Herrington & Sutcliffe and Morgan, Lewis & Bockiu represented David Schulman. Trawsfynydd Therapeutics, Inc. (“Trawsfynydd”)...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented Royalty Pharma, and Orrick Herrington & Sutcliffe represented Ferring Pharmaceuticals in the deal. Royalty Pharma plc (Nasdaq: RPRX) and Ferring Pharmaceuticals announced...
You must be a Standard 1 Year member to access this content.
Orrick advised Sosei Heptares. Sosei Heptares has announced its acquisition for U.S.$466 million (JPY 65 billion) of Idorsia’s pharmaceuticals business in Japan and APAC (ex-China). Sosei...
You must be a Standard 1 Year member to access this content.
Orrick and Cirio advised Ipsen on the deal, while Paul, Weiss, Rifkind, Wharton & Garrison and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo advised Albireo. Ipsen...
You must be a Standard 1 Year member to access this content.
Orrick advised BioAtla on the deal. Clinical-stage biotechnology company BioAtla, Inc. (Nasdaq: BCAB) announced the sale of 9,745,128 shares of its common stock at a price of...
You must be a Standard 1 Year member to access this content.
Orrick Herrington & Sutcliffe advised Ipsen on the deal. Global biopharmaceutical company Ipsen (Euronext: IPN; ADR: IPSEY) announced its definitive agreement to acquire Epizyme (Nasdaq: EPZM), a...
You must be a Standard 1 Year member to access this content.
Fredrikson & Byron represented HelpSystems in the transaction while Greenberg Traurig advised Tripwire Interactive. HelpSystems, a software company focused on helping organizations secure and automate their...
You must be a Standard 1 Year member to access this content.
Orrick Herrington & Sutcliffe advised Dompé on the deal. Dompé farmaceutici S.P.A (Dompé) announced its multi-year, multi-program strategic research and development collaboration with Engitix Ltd., a biopharmaceutical...
You must be a Standard 1 Year member to access this content.
Orrick Herrington & Sutcliffe LLP advised Rafael Pharmaceuticals on the deal. Rafael Pharmaceuticals, a clinical-stage oncology company, announced its proposed merger with Rafael Holdings, Inc., (NYSE: RFL)....
You must be a Standard 1 Year member to access this content.
Orrick Herrington & Sutcliffe LLP advised Guide Therapeutics on the deal. Guide Therapeutics (GuideTx), a developer of nonviral drug delivery vehicles for genetic medicines, announced its acquisition...
You must be a Standard 1 Year member to access this content.
